77 results about "Keratinocyte growth factor" patented technology

The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present invention provides methods for treatment of wounds with human skin equivalents engineered to express exogenous polypeptides.

The invention discloses a compound growth factor collagen sustained-release carrier material for promoting repair of various traumas in oral and maxillofacial regions and a method for preparing the same. In order to overcome the defect of poor curative effect existing in the conventional medicaments for treating the traumas of various tissues such as an oral cavity and a face, a bioactive collagen sustained-release material is prepared by combining collagen modified by liposome, chitosan, glycosaminoglycan and the like with one or more of a basic fibroblast growth factor (bFGF), a platelet derived growth factor (PDGF-BB), a vascular endothelial growth factor (VEGF) and a keratinocyte growth factor (KGF). The bioactive collagen sustained-release material is characterized in that: each gram of bioactive collagen sustained-release material contains not less than 10ng of growth factors, and the bioactive collagen sustained-release material has the obvious effect of treating various facial tissue traumas such as tooth extraction wound, oral ulcer, facial nerve injury, mandibular defect and the like. The collagen sustained-release carrier material can continuously release an effective amount of the growth factors to the wound for a long time, fully exert the inducing effect of the growth factors and obviously shorten the time for wound healing so as to fulfill the aim of treatment.

The present invention provides long-term stable formulations of lyophilized keratinocyte growth factor and methods for making a lyophilized composition comprising keratinocyte growth factor.

The present invention provides a method for maintaining and promoting hair thickening by increasing the expression of keratinocyte growth factor (FGF-7) in hair follicle cells, and preferably dermal papilla cells, a composition for increasing expression of FGF-7 that contains adenosine and/or a derivative thereof, and particularly, an external scalp preparation for maintaining and promoting hair thickening.

The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.

The invention relates to a follicular cell activator composition and preparation and their application. A follicular cell activator comprises at least two of a bFGF (basic fibroblast growth factor), an KGF or KGF1 (keratinocyte growth factor or keratinocyte growth factor 1), a KGF2 (keratinocyte growth factor 2), an IGF-1 (insulin-like growth factor 1), a VEGF (vascular endothelial growth factor),an HGF or HGF alpha (hepatocyte growth factor or hepatocyte growth factor alpha), an FGF18 (fibroblast growth factor 18), an SCF (stem cell factor), an FGF20 (fibroblast growth factor 20), an NGF (never growth factor), a GH (growth hormone) and Wnt3a protein. The follicular cell activator preparation herein can regulate proliferation, differentiation, regeneration and metabolism of follicular cells, and improve microcirculation to restore follicles and effectively treat seborrheic alopecia and other types of hair loss.

The invention discloses a skin anti-ageing skin composition. The skin anti-ageing skin composition comprises the following components: components A which comprise 0.50-10.0 parts by weight of collagen, 20-40 parts by weight of glycerinum, 3-8 parts by weight of hydrolyzed rice protein and 3-8 parts by weight of sweet almond seed extract, and components B which comprise (based on the weight of the components (A) 1000IU/g-50000IU/g of sodium hyaluronate and 100 IU/g-5000 IU/g of keratinocyte growth factor. The skin anti-ageing skin composition disclosed by the invention is free of side effect, can be used for effectively improving the couperose skin, repairing skin injury, promoting production of novel cells and resisting skin aging, and has obvious scar-removing and radiation-preventing effects, so that the skin is tender and perfect, and therefore, abnormal skin manifestations such as stains and hyperpigmentation can be eliminated; besides, the skin anti-ageing active composition can be independently used or added with other components for being processed into various skincare products or cosmetics.

The present invention relates to various newly identified polynucleotides, polypeptides encoded by such polynucleotides, uses of such polynucleotides and polypeptides, and production of such polynucleotides and polypeptides. More specifically, the polypeptide of the present invention is keratinocyte growth factor, sometimes referred to hereinafter as "KGF-2," and formerly referred to as fibroblast growth factor 12 (FGF-12). The present invention also relates to the therapeutic use of KGF-2 for promoting or accelerating wound healing. The present invention also relates to new mutant forms of KGF-2 which show enhanced activity, increased stability, higher yield or better solubility.

The invention discloses a mesenchymal stem cell and the application thereof in resisting HIV-1 (human immunodeficiency virus), and particularly relates to a mesenchymal stem cell of a secreted-expression high-concentration keratinocyte growth factor (KGF), and the mesenchymal stem cell is produced through a micro-carrier culturing system. According to the invention, the mesenchymal stem cell can be used for promoting the development of the thymus gland, maintaining the functions of the thymus gland, and enhancing the immunologic function of specific T cells through increasing the output of T lymphocytes to peripheral blood, thereby achieving an effect of treating HIV-1 infection, and providing an effective new strategy for the clinical treatment of the acquired immunodeficiency syndrome.

The invention discloses a composition for promoting physiologically regulative regeneration of a damaged tissue. The composition comprises such components as albumin, epidermal growth factor, transforming growth factor alpha, keratinocyte growth factor, basic fibroblast growth factor, platelet-derived growth factor, vascular endothelial growth factor, interleukin-8 and granulocyte-macrophage colony stimulating factor. The eight protein factors are combined for use to comprehensively develop the physiological tissue repair function; the eight protein factors functionally promote each other; based on the own physiological tissue recovery mechanism of the human body, the wound healing is accelerated and the wound healing quality is improved, including recovering the structure and the functions of the normal skin tissue. Each cell factor-containing component has clear mechanism of action without any potential toxic and side effect and objectionable odor. Such a combined recovery agent is capable of recovering the normal structure and the physiological functions of tissues more quickly under the physiological conditions of the human body.

The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of keratinocyte growth factor (KGF) to result in keratinocyte growth factor (KGF) proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

The invention provides a serum composite capable of moisturizing, whitening, tightening and lifting. The serum composite consists of serum and freeze-dried powder, wherein the serum consists of the following ingredients by weight percent: 3-8% of propylene glycol, 2-5% of glycerinum, 0.05-0.1% of tremella heteropolysaccharide, 2-5% of bio-saccharide gum-1, 0.1-0.5% of an algarroba seed extractive,2-5% of a purple perilla extractive, 2-5% of PCA (Pyrrolidone carboxylic acid)-Na, 2-5% of a citrullus vulgaris fruit extractive, 0.2-0.5% of a flos honeysuckle extractive, 2-4% of xylitol, 0.05-0.1%of alpha-arbutin, 2-4% of a magnolia sieboldii extractive, 0.5-1% of a lens culinaris fruit extractive, 0.5-1% of an auxiliary agent, 1-2% of an apple fruit extractive, 0.5-3% of PPG (polypropylene glycol)-10 methyl glucose ether, 0.5-2% of bis-PEG (polyethylene glycol)-18 methyl ether dimethylsilane, 0.01-0.1% of sodium hyaluronate, 0.5-1% of a digua fig stem extractive and the balance of water,wherein the freeze-dried powder consists of the following ingredients: EGF (Epidermal Growth Factor), KGF (Keratinocyte Growth Factor), BFGF (B-Fibroblast Growth Factor) and mannitol. The invention also provides a preparation method thereof. The serum composite provided by the invention adopts different plant extractives to mutually act and compound to obtain a growth factor. The serum compositehas favorable multiple efficacies of moisturizing, whitening, tightening, lifting, balancing facial water and oil, resisting oxidization and ageing and the like, and contains no preservative.

The invention relates to the field of medicines, in particular to a gamma-polyglutamic acid biological dressing and a preparation method thereof. The gamma-polyglutamic acid biological dressing comprises a packing material, a base material and a dressing agent, wherein the dressing agent is prepared from the following raw materials of amma-polyglutamic acid with Mr being greater than or equal to 200,000 and less than 2 millions, low-molecular-weight hyaluronic acid with Mr being greater than or equal to 10,000 and less than 200,000, oligomeric hyaluronic acid, with Mr being less than 10,000, epidermal growth factor, keratinocyte growth factor, glycerol, hydroxyethyl cellulose, phenoxyethanol and water, wherein the Mr is a relative molecular weight. The biological dressing disclosed by theinvention has a stronger healing promoting effect, and can be used for remarkably improving the healing quality, reducing pigmentation in a wound healing process, relieving itching and stabbing pain in the wound healing process and realizing a better treatment and scalding effect.

The invention discloses a recombinant human keratinocyte factor KGF-2 (keratinocyte growth factor-2) environment-sensitive eye transfer system and application thereof, and particularly relates to an environment-sensitive eye transfer system taking KGF-2 silicon plastid as a core and a preparation method and application thereof, and the transfer system comprises the following components by weight: 1.2-3.5 wt% of KFG-2, 1-10wt% of organic - inorganic compound lipid, 6-20wt% of a protective agent and 1-5wt% of substrate gel. The KGF-2 silicon plastid is prepared by thin film hydration ultrasound, and further the environment sensitive eye transfer system is prepared. Compared with the prior art, the product can obviously improve the stability of the KGF-2 and prolong the retention time of the KGF-2 in the eye, is conducive to the absorption and utilization of the KGF-2, has good repairing effects on various corneal ulcers, also can moisten the eyeball and alleviate the dry eye symptoms, has good relieving effects on eye fatigues, and also is suitable for the repairing of other oral mucosas and mucosa trauma and the repairing after skin beauty treatment.

The present invention relates to the administration of Keratinocyte Growth Factor-2 (KGF-2) to stimulate proliferation of platelets and to increase levels of fibrinogen, albumin, globulin and total serum protein. Further, the present invention relates to administering KGF-2 to protect or treat the bladder and prostate. Moreover, the present invention relates to administering KGF-2 to stimulate growth of nasal, oral, and esophageal mucosa, lacrimal glands, salivary glands and Goblet cells.

The invention provides a gas-liquid level growth medium for melanin and keratinocytes for constructing a reconstituted skin model and relates to the technical field of tissue engineering. Gathered and abnormally germinated melanin model tissue sections prove that the main reason lies in non-uniform melanin germination and excessive germination of the keratinocytes. The growth medium has the characteristics of promoting uniform melanocytes germination and inhibiting excessive germination of the keratinocytes, and attachment and proliferation of melanocytes are promoted by adding cholera toxin and TPA (12-O-tetradecanoylphorbol-13-acetate). In terms of 500 ml, the gas-liquid level growth medium for the melanin and the keratinocytes for constructing the reconstituted skin model comprises 500 ml of cutin serum-free medium K-SFM, 2-30 mu g of insulin, 10-800 mu g of hydrocortisone, 10-200mg of bovine pituitary extract, 20-2000 mu g of an upper epidermal growth factor, 1-1500 mu g of a basic fibroblast growth factor, 5-80 mu g of a keratinocyte growth factor, 20-200 ng of TPA, 10-200 mg of CaCl2 and 20-200 nM of cholera toxin.

A gene sequence of a human-derived keratinocyte growth factor-2, an expression vector and a production method are disclosed. Through designing the gene sequence, of the human-derived keratinocyte growth factor-2, meeting codon preference properties of a target plant, the suitable plant expression vector including the KGF-2 gene sequence is constructed, the plant expression vector is transferred tothe target plant, and multiple screening is performed to obtain a transgenic plant having a high protein expression level, wherein the target plant is medicago sativa. The production cost is greatlyreduced when the medicago sativa is utilized to express the human-derived KGF-2 than the production cost when microorganism expression systems are utilized to express the human-derived KGF-2, and protein products can be correctly folded to avoid generation of inclusion bodies. The gene sequence, the expression vector and the method have good application prospects.

The invention discloses a stem cell bioactive composition and a preparation method and application thereof. The stem cell bioactive composition comprises 1.69 to 22.24 pg/mL of EGF (epidermal growth factor), 2443.17 to 4459.43 pg/mL of bFGF (basic fibroblast growth factor), 1.44 to 134.36 pg/mL of beta-NGF (Beta-nerve growth factor), 1.55 to 355.14 pg/mL of VEGF (vascular endothelial growth factor), 11.87 to 159.70 pg/mL of PDGF-DD (platelet-derived growth factor), 135.79 to 688.13 pg/mL of KGF (keratinocyte growth factor), and 1176.99 to 3825.79 pg/mL of TGF-Beta1 (transforming growth factor beta-1); the stem cell bioactive composition has high purity, high yield and high bioactivity.